東寶生物(300239.SZ):2019年淨利預增0.07%-8.9%
格隆匯1月14日丨東寶生物(300239.SZ)披露2019年度業績預告,公司預計2019年1-12月歸屬於上市公司股東的淨利潤為3400萬元–3700萬元,同比增長0.07%-8.90%。業績變動原因如下:
1、公司明膠業務穩步發展,銷量、收入較上年同期增加。
2、膠原蛋白業務穩定、毛利率增長。
3、公司加大了研發投入力度,研發投入較上年同期增加,研發費用相應增加,對當期利潤造成一定影響。
4、2019年度公司非經常性損益對淨利潤的貢獻金額預計為850-950萬元,較上年同期增加492.45-592.45萬元。非經常性利潤貢獻主要是公司收到的創新升級政府補助、財政扶持資金、以無形資產對外投資以及遞延收益攤銷轉當期損益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.